Published in Eur J Health Econ on December 07, 2014
Utility Estimation for Pediatric Vesicoureteral Reflux: Methodological Considerations Using an Online Survey Platform. J Urol (2016) 0.75
Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation. Qual Life Res (2017) 0.75
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Modeling valuations for EuroQol health states. Med Care (1997) 21.66
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med (2013) 6.08
The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes (2003) 5.26
The time trade-off method: results from a general population study. Health Econ (1996) 4.17
Hepatitis C: the clinical spectrum of disease. Hepatology (1997) 3.94
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes (2007) 3.66
The utility of different health states as perceived by the general public. J Chronic Dis (1978) 3.65
Introducing economic and quality of life measurements into clinical studies. Ann Med (2001) 2.99
Modelling valuations for health states: the effect of duration. Health Policy (1996) 2.91
Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology (2001) 2.90
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis (2010) 2.71
Incorporating process utility into quality adjusted life years: a systematic review of empirical studies. Pharmacoeconomics (2013) 2.12
A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med (2005) 2.07
Changing preferences for survival after hospitalization with advanced heart failure. J Am Coll Cardiol (2008) 1.96
Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol (2013) 1.95
Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med (2012) 1.80
Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord (1998) 1.75
Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments. Med Care (2010) 1.69
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology (2011) 1.67
The minimally clinically important difference in generic utility-based measures. COPD (2005) 1.56
Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol (2012) 1.53
Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess (2006) 1.50
Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol (2001) 1.48
A community-based study of acne-related health preferences in adolescents. Arch Dermatol (2008) 1.44
Are QALYs based on time trade-off comparable?--A systematic review of TTO methodologies. Health Econ (2005) 1.41
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
Health-state utilities in liver disease: a systematic review. Med Decis Making (2008) 1.35
The "utility" of the Time Trade-Off method in cancer patients: feasibility and proportional Trade-Off. J Clin Epidemiol (1995) 1.32
Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health (2007) 1.32
Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry (2012) 1.28
Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes (2004) 1.19
Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol (2012) 1.13
The influence of subjective life expectancy on health state valuations using a 10 year TTO. Health Econ (2009) 1.10
Patient preferences and assessment of likely adherence to hepatitis C virus treatment. J Viral Hepat (2010) 1.10
Valuing health States for use in cost-effectiveness analysis. Pharmacoeconomics (2008) 1.09
Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ (2010) 1.08
The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States. Clin Liver Dis (2013) 1.07
The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol (2014) 1.05
Health values of patients with chronic hepatitis C infection. Arch Intern Med (2004) 1.04
Current status and future directions in the management of chronic hepatitis C. Virol J (2012) 0.99
It's all in the name, or is it? The impact of labeling on health state values. Med Decis Making (2011) 0.97
Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM (2012) 0.97
Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open (2013) 0.95
Utility scores and treatment preferences for clinical early-stage cervical cancer. Value Health (2011) 0.93
Patient preferences for different severities of and treatments for overactive bladder. Female Pelvic Med Reconstr Surg (2011) 0.93
Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review. Hepat Mon (2013) 0.92
Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics (2008) 0.91
Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl Health Econ Health Policy (2013) 0.91
Framing and labelling effects in health descriptions: quality adjusted life years for treatment of breast cancer. J Clin Epidemiol (1993) 0.90
Hepatitis C virus infection and risk of cancer: a population-based cohort study. Clin Epidemiol (2010) 0.90
Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients. Support Care Cancer (2012) 0.90
Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Pharmacoeconomics (2009) 0.89
Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clin Ther (2013) 0.89
Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. Aliment Pharmacol Ther (2010) 0.88
Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health (2011) 0.87
Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol (2007) 0.87
Development and testing of a utility measure for major, unipolar depression (McSad). Qual Life Res (2000) 0.87
The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol (1996) 0.86
Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review. World J Hepatol (2013) 0.85
Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study. Health Qual Life Outcomes (2012) 0.85
New agents for the treatment of hepatitis C in patients co-infected with HIV. Ther Adv Infect Dis (2013) 0.85
Health-related quality-of-life assessment of prenatal diagnosis: chorionic villi sampling and amniocentesis. Genet Test (2002) 0.85
Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther (2013) 0.84
Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population. BMC Gastroenterol (2013) 0.84
Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PLoS One (2014) 0.84
Thirty down, only ten to go?! Awareness and influence of a 10-year time frame in TTO. Qual Life Res (2013) 0.83
Examination of assumptions in using time tradeoff and standard gamble utilities in individuals with spinal cord injury. Arch Phys Med Rehabil (2012) 0.82
Health state utilities for skeletal-related events secondary to bone metastases. Eur J Health Econ (2013) 0.82
Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database Syst Rev (2013) 0.82
Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions. Clin Pharmacokinet (2013) 0.81
Excess morbidity in the hepatitis C-diagnosed population in Scotland, 1991-2006. Epidemiol Infect (2010) 0.81
Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions. Braz J Infect Dis (2013) 0.81
Telaprevir: changing the standard of care of chronic hepatitis C. J Postgrad Med (2013) 0.80
Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes. Patient (2013) 0.79
Boceprevir in chronic hepatitis C infection: a perspective review. Ther Adv Chronic Dis (2012) 0.79
Interferon-based treatment of chronic hepatitis C. Biochimie (2007) 0.79
Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. Patient Prefer Adherence (2013) 0.79
Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom. Leuk Lymphoma (2011) 0.79
Adherence to chronic hepatitis C treatment regimen: first report from a referral center in iran. Hepat Mon (2013) 0.78
Utility assessment among cataract surgery patients. J Cataract Refract Surg (2005) 0.78
Management of side-effects. Clin Res Hepatol Gastroenterol (2011) 0.78
The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation. Eur J Health Econ (2015) 0.75
Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK. Patient Prefer Adherence (2015) 0.84
A qualitative examination of the content validity of the EQ-5D-5L in patients with type 2 diabetes. Health Qual Life Outcomes (2015) 0.77
Health state utilities associated with adult attention-deficit/hyperactivity disorder. Patient Prefer Adherence (2014) 0.75
The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation. Eur J Health Econ (2015) 0.75
Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation. Qual Life Res (2017) 0.75